Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
ICH Q7 provides guidance on the GMP requirements for manufacturing of APIs to assure that APIs meet the requirements for quality and purity. It is jointly enforced by FDA, EMA, and all ICH member health authorities.
What this does not cover
stated in the document's own scope- Covers GMP for active pharmaceutical ingredients, not for finished dosage forms — that is the finished-product GMP of EU GMP Part I / PIC/S.
- Covers APIs, not excipients; GMP for excipients is addressed by the Joint IPEC-PQG Guide, because Q7 governs actives only.
- Applies from the defined API starting material onward; earlier chemical or biological steps sit outside GMP scope as Q7 defines it.
- Sets manufacturing GMP, not the development or lifecycle-management approach for the drug substance, which are ICH Q11 and Q12.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH Q7 is the harmonised Good Manufacturing Practice guide for active pharmaceutical ingredients — the APIs that become the active substance of a finished drug. It translates GMP principles into the specifics of API manufacture, from the point where a defined starting material enters the process through to the finished active substance. It covers the quality unit and its responsibilities, buildings and facilities, process equipment, documentation, materials management, production and in-process controls, packaging and labelling, storage and distribution, laboratory controls, validation, change control, and the handling of returns, complaints, and recalls. A dedicated section addresses APIs made by cell culture or fermentation.
Scope & applicability
All API manufacturers supplying to regulated markets globally. Covers the complete API manufacturing process from starting material through packaging.
Legal basis & how it acquires force
Q7 is an ICH Quality (Q) guideline, finalised at Step 4 in November 2000. An ICH guideline is not itself law; it acquires force when each region implements it. The European Union adopted Q7 as Part II of the EU GMP Guide (Basic Requirements for Active Substances used as Starting Materials); the FDA issued it as a guidance for industry that describes how it interprets the API GMP expectations under the Federal Food, Drug, and Cosmetic Act; and Japan gives it effect through MHLW. So a manufacturer complies with the regional instrument, and Q7 is the common text those instruments were harmonised to.
Document structure
| Part | Covers |
|---|---|
| Quality management | The quality unit, its responsibilities, internal audits, and product quality review |
| Buildings, facilities, and equipment | Premises design, utilities, containment, and process equipment and its cleaning |
| Documentation and materials management | Records, specifications, and the receipt, testing, and control of materials |
| Production and in-process controls | Manufacturing operations, in-process sampling, blending, and contamination control |
| Validation and change control | Process validation, cleaning validation, and the change-control system |
| APIs from cell culture/fermentation and clinical-trial APIs | Biotechnological/biological API specifics and GMP for APIs used in clinical trials |
Key requirements
- Impurity profiles for all APIs with limits justified by clinical and toxicological data
- Starting material specifications and control strategy
- In-process controls and specifications throughout the synthesis
- Cleaning validation for shared equipment with health-based exposure limits
- Laboratory controls including reference standards and reagent qualification
Implementation tips
- Elemental impurity risk assessment per ICH Q3D should be conducted and referenced in the API dossier
- Cleaning validation limits should be calculated using PDE values — not the historical 10 ppm/0.1% criteria
Revision notes
Original November 2000. Q&A documents issued 2003-2016. No formal revision — considered sufficiently mature. ICH Q3D (elemental impurities, 2014) supplements Q7 for inorganic impurity controls.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Q7 is the API-level companion to the finished-product GMP frameworks — EU GMP Part I and the PIC/S GMP Guide — and its adoption as EU GMP Part II makes it the reference across the ICH and PIC/S regions. It connects upward to the development and control guidelines Q8, Q11, and Q12, and it explicitly places excipients outside its scope, since it governs active substances rather than the inactive ingredients that IPEC guidance addresses.
ICH Q7: frequently asked questions
Quick answers to common questions about ICH Q7.
Does ICH Q7 apply to excipients?
No. Q7 is the GMP guide for active pharmaceutical ingredients — the active substance. Excipients are outside its scope; the reference for excipient GMP is the Joint IPEC-PQG Good Manufacturing Practices Guide.
Is ICH Q7 legally binding?
Not by itself. Q7 is a harmonised ICH guideline; it becomes enforceable through each region’s own law — the EU adopted it as Part II of the GMP Guide, the FDA issued it as a guidance for industry, and Japan implements it through MHLW.
Where does GMP begin under ICH Q7?
Q7 applies from the introduction of the defined API starting material into the process onward. Steps before that point are not covered by the GMP expectations Q7 sets for active-substance manufacture.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.